A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

Suggested remit: To appraise the clinical and cost effectiveness of Sasanlimab with BCG within its marketing authorisation for treating bladder cancer.

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® ...

These leaflets are suspended from the muscular atrioventricular junction apart from a small area of membranous septum. They are joined by papillary muscles: the medial papillary muscle between the ...

The gene therapy nadofaragene firadenovec demonstrated strong clinical activity in Japanese patients with BCG-unresponsive ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.

Skeletal muscles are voluntary muscles that can be consciously controlled, such as the muscles of your neck, arms, and legs. It makes up 30% to 40% of human body weight in a healthy person. The ...